Fig. 6
From: MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat
Fimepinostat is an effective SCLC treatment in vivo. Platinum resistant mouse SCLC cell lines (A) B37R and (B) EN84R, human cell line (C) NCI-H209 or PDX cell lines (D) PDX102 and (E) PDX109 were transplanted subcutaneously into the flanks of recipient mice. When tumors reached 150-200 mm.3 mice were treated with fimepinostat (70 mg/Kg, daily, per os) and tumor volume measured with calipers. Plotted data is the mean ± SEM for cohorts of at least 8 mice per group. Statistically significant tumor reduction was calculated by paired student’s t-test (**p < 0.005, ***p < 0.001, ****p < 0.0001)